Investigational drug · Phase 3
JAB-21822
Also called: Glecirasib Citrate, KRAS G12C inhibitor
Not approved by FDA. In 10 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
10
9 still active
All registered trials
13
Any phase or sponsor naming "JAB-21822"
First trial start
2021
Jul 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JAB-21822", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- KRAS P.G12C
- Solid Tumor
- NSCLC
- KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment
- Advanced Colorectal Cancer
- Small Intestinal Cancer
- Appendiceal Cancer
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "JAB-21822" as an intervention, largest first.
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationPivotal-lookingRecruiting
Allist Pharmaceuticals, Inc.Industry
NCT06416410 · 392 participants (planned) · Start Aug 7, 2024 · Primary completion Sep 30, 2029
Drug: JAB-21822; Tislelizumab and 3 more · For: Advanced Non-squamous Non-small-cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer
Sites: Hefei, China; Beijing, China; Fuzhou, China · 37 sites in all
- A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaActive, not recruiting
Allist Pharmaceuticals, Inc.Industry
NCT05009329 · 315 participants · Start Jul 26, 2021 · Primary completion Aug 2026
Drug: JAB-21822; JAB-21822 and 1 more · For: NSCLC; Solid Tumor
Sites: Beijing, China
Allist Pharmaceuticals, Inc.Industry
NCT05288205 · 240 participants (planned) · Start Apr 14, 2022 · Primary completion Mar 2027
Drug: JAB-21822; JAB-3312 · For: KRAS P.G12C; Non-small Cell Lung Cancer; Colorectal Cancer and 1 more
Sites: Hefei, China; Beijing, China; Fuzhou, China · 27 sites in all
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06563999 · 120 participants (planned) · Start Nov 1, 2024 · Primary completion Nov 1, 2027
Drug: Sunvozertinib; Crizotinib and 7 more · For: Lung Cancer Stage III; Mutation
Sites: Guangzhou, China
Allist Pharmaceuticals, Inc.Industry
NCT05276726 · 104 participants (planned) · Start Aug 17, 2022 · Primary completion Aug 2027
Drug: JAB 21822 · For: Non-small Cell Lung Cancer
Sites: Beijing, China; Chongqing, China; Xiamen, China · 21 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT06008288 · 88 participants (planned) · Start Oct 27, 2023 · Primary completion Dec 31, 2026
Drug: JAB-21822 · For: KRAS P.G12C; Pancreatic Cancer; Solid Tumor
Sites: Hefei, China; Beijing, China; Fuzhou, China · 31 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT06162169 · 66 participants · Start Nov 25, 2023 · Primary completion Feb 20, 2024
Drug: JAB-21822; Itraconazole and 3 more · For: Healthy Subjects
Sites: Beijing, China
- JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationActive, not recruiting
Allist Pharmaceuticals, Inc.Industry
NCT05194995 · 48 participants · Start Feb 17, 2022 · Primary completion Apr 30, 2025
Drug: JAB-21822; Cetuximab · For: Advanced Colorectal Cancer; Small Intestinal Cancer; Appendiceal Cancer
Sites: Beijing, China; Nanning, China; Harbin, China · 17 sites in all
- Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLCNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07339839 · 42 participants (planned) · Start Mar 1, 2026 · Primary completion Sep 30, 2027
Drug: Glecirasib; Ivonescimab · For: NSCLC Stage IV; KRAS G12C
- JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRCActive, not recruiting
Jian LiAcademic, hospital or other
NCT06838338 · 30 participants (planned) · Start Mar 20, 2025 · Primary completion Mar 2026
Drug: JAB-21822; standard second-line chemotherapy and 1 more · For: Colorectal Cancer
Sites: Beijing, China; Hohhot, China; Shanghai, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting RAS Signaling Pathways: Molecular Regulation, FDA-Approved Inhibitors, Clinical Advances, and Patent Innovations.
Chauhan A, Prajapati V, Singh AK, et al. · Drug Dev Res 2026
- PRMT1 blockade reverts resistance to KRAS (G12C) inhibition through modulating ferroptosis signalling.
Fu X, Wang Z, Yu X, et al. · Int J Oncol 2026
- AKR1B1-dependent ferroptosis defense contributes to KRASG12C inhibitor resistance in pancreatic ductal adenocarcinoma.
Guan X, Yang W, Yao Z, et al. · Drug Resist Updat 2026
- Next-generation KRAS G12C inhibitor improves survival in lung cancer.
Harjes U · Nat Med 2026
- Mechanisms of Resistance to KRAS G12C Inhibitors and the Rationale for Targeting the PI3K/AKT/mTOR Pathway in Advanced NSCLC.
Devanahally S, Paul S, Tiwari P, et al. · Mini Rev Med Chem 2026
- Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer.
Cheng L, Hou SJ, Nie Q, et al. · Bioorg Chem 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.